Figure 2.
Rates of DFS, relapse, CR2, and death over 5 years from the time of AML diagnosis for patients with adverse-risk disease. (A) IC and allo-SCT, (B) IC without allo-SCT, (C) aza-ven and allo-SCT, and (D) aza-ven without allo-SCT.
Rates of DFS, relapse, CR2, and death over 5 years from the time of AML diagnosis for patients with adverse-risk disease. (A) IC and allo-SCT, (B) IC without allo-SCT, (C) aza-ven and allo-SCT, and (D) aza-ven without allo-SCT.
